Approval of Qdenga dengue vaccine in India

5 entries over 9 days, from 21 July 2026 to 29 July 2026.

01
21 July

India approves QDENGA dengue vaccine

DCGI has granted market authorisation to Takeda Biopharmaceuticals India’s QDENGA (TAK-003), the first dengue vaccine approved in India.
Target demographic: Individuals aged 4 to 60 years.
Vaccine type: Live-attenuated tetravalent vaccine covering all four dengue virus serotypes.
Administration: Two-dose regimen with a three-month interval between doses.
No pre-vaccination screening required; effective regardless of prior dengue infection history.
Clinical basis: Approval supported by 19 global clinical trials (Phase I, II, and III) involving over 28,000 participants.
Efficacy data: 80.2% against virologically confirmed dengue (12 months post-second dose) and 90.4% against hospitalisation (18 months post-second dose).
Public health context: Dengue cases in India have increased nearly 11-fold over the last two decades, with India accounting for approximately one-third of the global burden.
Global status: QDENGA is approved in 43 countries across Asia, Latin America, and Europe.

02
25 July

Qdenga dengue vaccine approval

CDSCO has granted approval for Qdenga, India's first dengue vaccine, developed by Japan-based Takeda.
Qdenga has received WHO prequalification and is licensed in over 40 countries.
Dengue is caused by four antigenically distinct serotypes; effective vaccines must induce immunity against all four to avoid antibody-dependent enhancement.
Unlike the earlier Dengvaxia, Qdenga does not require screening for prior dengue infection before administration.
Qdenga requires a two-dose regimen administered three months apart.
Efficacy varies by serotype: highest protection against DENV-2, followed by DENV-1, with uncertainty regarding DENV-3 and DENV-4 in seronegative individuals.
Rising prevalence of DENV-3 in India poses a potential risk to vaccine efficacy if the serotype dominates during monsoon seasons.
Challenges for rollout include ensuring the second dose is administered to mobile populations and managing high costs through tiered pricing negotiations.
The TIDES trial indicated concerns regarding 'negative efficacy' against DENV-3-related hospitalisation among seronegative children.

03
27 July

Dengue vaccine approval in India

India has approved Qdenga, its first dengue vaccine, manufactured by Takeda (Japan), for individuals aged 4-60 years.
The vaccine is tetravalent, intended to protect against all four dengue virus serotypes (DENV-1 to DENV-4).
Dengue infection mechanism: Primary infection creates antibodies; secondary infection by a different serotype can lead to Antibody-Dependent Enhancement (ADE), increasing the risk of severe disease.
Phase-3 trial data (20,000 participants) showed an overall efficacy of 80% in preventing infection and hospitalisation.
Efficacy was 82% for seropositive individuals and 75% for seronegative individuals at baseline.
Safety signal: Seronegative children vaccinated with Qdenga were 25% more likely to be infected by DENV-3 compared to unvaccinated children.
Efficacy against DENV-4 remains unknown due to low/absent case numbers in trials.
Researchers suggest pre-vaccination screening for dengue exposure is necessary to mitigate the risk of ADE in seronegative recipients.

04
28 July

Dengue vaccine approval in India

India has approved Qdenga, the country's first dengue vaccine, manufactured by Takeda (Japan).
The vaccine is approved for individuals aged 4-60 years, regardless of prior dengue exposure.
Dengue virus has four distinct serotypes (DENV-1 to DENV-4); immunity to one does not guarantee protection against others.
Antibody-Dependent Enhancement (ADE): A phenomenon where antibodies from a primary infection can enhance the severity of a secondary infection by a different serotype.
An effective dengue vaccine must be 'tetravalent', targeting all four serotypes equally to prevent ADE.
Phase-3 clinical trial data (20,000 participants) showed an overall efficacy of approximately 80%.
Data indicates 'variable VE' (Vaccine Efficacy): Seronegative children vaccinated with Qdenga were 25% more likely to be infected by DENV-3 compared to unvaccinated children.
Efficacy against DENV-4 remains unknown due to insufficient data.
Researchers suggest that screening for prior dengue exposure (serostatus) before vaccination is necessary to mitigate risks for seronegative individuals.

05
29 July

Dengue virus surveillance study

ICMR-VRDL network conducted a two-year nationwide surveillance study (2023-2025) on dengue serotypes.
Study analyzed 6,889 laboratory-confirmed samples from 45 labs across 25 States and Union Territories.
DENV-2 is the predominant serotype, accounting for over 50% of infections.
Hyper-endemicity: Eight States/UTs report all four serotypes; 15 report three circulating simultaneously.
Concurrent infection: Approximately 7% (one in 14) of patients infected with two or more serotypes simultaneously.
Clinical impact: Concurrent infections are associated with higher risks of severe manifestations, including low platelet counts and bleeding complications.
Public health implications: Need for continuous molecular surveillance to inform vaccine development and deployment strategies.
Vaccination status: No dengue vaccine currently in India's Universal Immunisation Programme; indigenous candidates in advanced development; international vaccine approved for import.

Questions from this story

Newest first. A story that ran for 9 days is exactly the kind the mains paper asks about as one question.

Discuss the public health implications of the hyper-endemic circulation of multiple dengue virus serotypes in India as highlighted by recent ICMR surveillance. 150 words · 29 July
The emergence of multiple circulating dengue serotypes poses significant challenges for disease management and vaccination strategies in India. Analyze the role of molecular surveillance in strengthening India's public health response to communicable diseases. 250 words · 29 July
Discuss the challenges in developing a tetravalent dengue vaccine, specifically addressing the phenomenon of Antibody-Dependent Enhancement (ADE) and its implications for public health policy in India. 150 words · 28 July
The introduction of new vaccines for endemic diseases requires a balance between rapid deployment and rigorous safety protocols. In the context of the recently approved dengue vaccine, analyze the necessity of serological screening prior to vaccination and the role of regulatory bodies in ensuring long-term safety monitoring. 250 words · 28 July
Discuss the challenges in developing a safe and effective tetravalent dengue vaccine, with specific reference to the phenomenon of Antibody-Dependent Enhancement (ADE). 150 words · 27 July
The approval of new vaccines for endemic diseases requires a balance between public health urgency and clinical safety protocols. In the context of the recently approved dengue vaccine in India, examine the necessity of serological screening and the implications of variable vaccine efficacy across different viral serotypes. 250 words · 27 July
Discuss the scientific challenges associated with developing an effective vaccine for dengue fever, particularly concerning the phenomenon of antibody-dependent enhancement. 150 words · 25 July
The approval of the Qdenga vaccine marks a significant milestone in India's public health response to dengue. Critically analyze the operational and epidemiological challenges that must be addressed to ensure an effective national rollout of this vaccine. 250 words · 25 July
Discuss the significance of the approval of the first dengue vaccine in India in the context of the country's rising disease burden and the challenges of managing vector-borne diseases. 150 words · 21 July
The introduction of new vaccines for endemic diseases is a critical component of public health strategy. Analyze the role of clinical trial data and regulatory oversight in ensuring the efficacy and safety of new medical interventions in India. 250 words · 21 July

Syllabus this story touches

Topics

250words.in · https://250words.in/stories/approval-of-qdenga-dengue-vaccine-in-india